Authentic Recombinant Human Proteins for Stem Cell Research
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications, such as disulfide bonds and glycosylation. Thus, HumanKine proteins possess not only the utmost quality for the best possible experimental results but are also affordable and scalable to meet the demands of industrial biopharmaceutical and cellular therapy customers. For applications in stem cell biology, immunology, and other disciplines, HumanKine growth factors and cytokines will enable achievement of the desired results regardless of project stage.
Stem Cell Research
HumanZyme develops and manufactures growth factors and cytokines for stem cell research applications. HumanKine® cytokines and growth factors are applied to stem cells for culture expansion or to drive differentiation into specific cell types. The human cell manufacturing system ensures native human glycosylation and other human-specific modifications that can result in better bioactivity and enhanced half-life.
HumanZyme develops and manufactures cytokines and cell culture media for immunology applications. Cytokines are cell signaling molecules that enable cell-cell communication, stimulation, differentiation, and other processes. HumanKine® cytokines, expressed in human cells, possess authentic human glycosylation, folding, disulfide bonds, and other modifications which are important for biological activity, half-life, and human-specific functions.
Human Cellular Therapy
HumanKine® cytokines and growth factors originally developed for stem cell applications are beginning to be utilized by cellular therapy developers in early stage trials. Growth factors and cytokines are often employed ex vivo to drive stem cell differentiation into potentially therapeutic cells. For many growth factors and cytokines, the industry lacks cGMP proteins needed for late stage clinical trials and subsequent regulatory approval of promising cellular therapies. HumanKine proteins can be adapted to cGMP production.